PARP4 - poly(ADP-ribose) polymerase family member 4 Gene

Also Known as PH5P; p193; ARTD4; PARPL; VPARP; VWA5C; PARP-4; VAULT3; ADPRTL1

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 143

About PARP4

Cytogenetic location: 13q12.12 Genomic coordinates (GRCh38): 13:24,420,931-24,512,778 (from NCBI)

This gene has 3 transcripts (splice variants), 186 orthologues and 11 paralogues. Ubiquitous expression in colon (RPKM 22.5), small intestine (RPKM 20.2) and 25 other tissues.

Summary

This gene encodes poly(ADP-ribosyl)transferase-like 1 protein, which is capable of catalyzing a poly(ADP-ribosyl)ation reaction. This protein has a catalytic domain which is homologous to that of poly (ADP-ribosyl) transferase, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly (ADP-ribosyl) transferase. Since this protein is not capable of binding DNA directly, its transferase activity may be activated by Other factors such as protein-protein interaction mediated by the extensive carboxyl terminus. [provided by RefSeq, Jul 2008]

PARP4 Products (3)

mRNA Protein Name
XM_047430097.1 XP_047286053.1 protein mono-ADP-ribosyltransferase PARP4 isoform X1
XM_011534932.3 XP_011533234.1 protein mono-ADP-ribosyltransferase PARP4 isoform X1
NM_006437.4 NP_006428.2 protein mono-ADP-ribosyltransferase PARP4

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Références Source
enables NAD+-protein ADP-ribosyltransferase activity IDA
IDA: Inferred from direct assay
25043379 GOA
enables NAD+-protein poly-ADP-ribosyltransferase activity IDA
IDA: Inferred from direct assay
10477748 GOA
enables enzyme binding IDA
IDA: Inferred from direct assay
15169895 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
15169895 GOA
Biological Process GO Annotation Evidence Références Source
involved in inflammatory response IMP
IMP: Inferred from mutant phenotype
12123754 GOA
involved in protein modification process IDA
IDA: Inferred from direct assay
10477748 GOA
Cellular Component GO Annotation Evidence Références Source
located in cytoplasm IDA
IDA: Inferred from direct assay
10477748 GOA
located in spindle microtubule IDA
IDA: Inferred from direct assay
10477748 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

PARP4 Protein Structure

BRCT

BRCT: BRCA1 C Terminus (BRCT) domain (3 - 81)

PARP

PARP: Poly(ADP-ribose) polymerase catalytic domain (378 - 565)

VIT

VIT: Vault protein inter-alpha-trypsin domain (621 - 733)

VWA_3

VWA_3: von Willebrand factor type A domain (876 - 1025)

  • 0
  • 300
  • 600
  • 900
  • 1200
  • 1500
  • 1724 a.a.
Protein Preferred Names Protein Names

protein mono-ADP-ribosyltransferase PARP4

  • 193 kDa vault protein

  • ADP-ribosyltransferase (NAD+

  • poly (ADP-ribose) polymerase)-like 1

  • ADP-ribosyltransferase diphtheria toxin-like 4

  • H5 proline-rich

  • I-alpha-I-related

  • PARP-related

  • PARP-related/IalphaI-related H5/proline-rich

  • poly [ADP-ribose] polymerase 4

  • poly(ADP-ribose) synthetase

  • poly(ADP-ribosyl)transferase-like 1

  • vault poly(ADP-ribose) polymerase

  • vault protein, 193-kDa

  • von Willebrand factor A domain containing 5C

Related Diseases

Diseases Alias
Osebold-Remondini Syndrome

  • Brachydactyly Type A6

  • Brachymesophalangy With Mesomelic Short Limbs And Carpal And Tarsal Osseous Abnormalities

  • Bda6

  • Brachydactyly, Type A6
Classic Pulmonary Blastoma

  • Biphasic Pulmonary Blastoma
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (4)
Cat. No. Nom du produit Effect
Pureté Rare Diseases
HY-10619 Niraparib Inhibitor 99.96% Yes
HY-10619A Niraparib hydrochloride Inhibitor 99.41% Yes
HY-10619B Niraparib tosylate Inhibitor 99.99% Yes
HY-10619E Niraparib tosylate hydrate Inhibitor 99.97% Yes

Clinical Phase

Bioactive Molecules (1)
Cat. No. Nom du produit Effect
Pureté Phase
HY-150207 RBN-3143 Inhibitor 99.29% Phase 1

Pre-clinical Phase

Bioactive Molecules (6)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-136979 RBN012759 Inhibitor 99.33% Unkown
HY-148566 OUL232 Inhibitor 99.86% Unkown
HY-148754 PARP10-IN-3 Inhibitor 98.72% Unkown
HY-148753 PARP10-IN-2 Inhibitor 98.02% Unkown
HY-155993 YCH1899 Inhibitor 99.39% Unkown
HY-W294889 OUL245 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Rattus norvegicus PARP4 RGD RGD:1310524
Felis catus PARP4 VGNC VGNC:102280
Mus musculus PARP4 MGD MGI:2685589
Others PARP4 NCBI